NewsSource: EClinCloud

How Much Do You Know About Routine Diagnostic Assessment of Chronic Obstructive Pulmonary Disease (COPD)? A Must-Save Guide!

3 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud. Author: EClinCloud.

Article illustration

Patient profile: 62-year-old male with a 30-year smoking history, presenting with persistent cough, dyspnea, chest tightness, and shortness of breath...

Article illustration

Watch Out for COPD!

Article illustration

Article illustration


What Is COPD?

COPD is short for chronic obstructive pulmonary disease, a preventable and treatable disease characterized by persistent airflow limitation that is closely associated with chronic bronchitis and emphysema[1]. Patients often overlook the long-term adverse effects of these recurrent pulmonary inflammations on the body, only realizing they are living in the shadow of COPD when they seek treatment for dyspnea.

Article illustration
Article illustration

Therefore, when patients with long-term pulmonary inflammation develop symptoms such as shortness of breath, breathlessness, or dyspnea after exertion, there should be high vigilance for the presence of COPD.


How Is the Severity of COPD Symptoms Assessed?

COPD questionnaires and scales can serve to assess the severity of COPD symptoms, the impact on daily life and treatment, and changes in the disease. As indicators or references, they provide patients and clinical trial research with multidimensional measurement data and assessment results.

Below, we introduce some of the most commonly used scales for assessing COPD symptoms and disease impact.


Most Commonly Used Scales for Routine Diagnostic Assessment of COPD!

In the clinical diagnosis of COPD, in addition to FEV1/FVC—a sensitive indicator for assessing airflow limitation—and post-bronchodilator FEV1, scales capable of assessing patient symptoms and severity include the modified Medical Research Council (mMRC) dyspnea scale (Figure 1) and the COPD Assessment Test (CAT).

The mMRC was the first scale developed to assess dyspnea (Table 1); it correlates well with other multidimensional health assessment methods and has some predictive value for future mortality risk[2].

Article illustration

Table 1: Modified MRC Dyspnea Scale (for reference only)

The CAT can be used to assess the impact of COPD on a patient's health and daily life. Compared with other COPD health assessment methods, the CAT evaluates 8 aspects—ranging from cough, phlegm, and chest tightness to daily activities, activities at home or outdoors, and sleep and energy—using 8 simple questions scored from 0 to 5. The higher the total score, the greater the impact on the patient's health[2].

Article illustration

The respective characteristics of the mMRC and CAT scales are summarized below:

Article illustration

In addition to scales used for routine diagnostic assessment, COPD scales in clinical trials can serve as efficacy endpoints in clinical research to measure treatment impact.

We will reveal more in the next issue—to be continued, see you next time!Article illustration

Article illustration

References

Article illustration

1. Chronic Obstructive Pulmonary Disease Group, Chinese Thoracic Society, Chinese Medical Association. Guidelines for the Diagnosis and Management of Chronic Obstructive Pulmonary Disease (2013 Revised Edition) (慢性阻塞性肺疾病诊治指南(2013 年修订版)), Chinese Journal of the Frontiers of Medical Science (中国医学前沿杂志), 2014, Vol. 6, No. 2.

2. GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2023 REPORT)




About EClinCloud

EClinCloud is a technology company focused on clinical R&D. It provides an integrated, interoperable, all-in-one cloud platform for clinical trials (including, across technology products and offerings such as eCOA, CTMS, eTMF, EDC, RTSM, and RM, solutions such as scale design, scale copyright management, linguistic validation, rater training, and data quality analysis) as well as clinical trial endpoint assessment technologies across therapeutic areas (including the central nervous system, ophthalmology, and others). Combining cutting-edge technology with life sciences data, EClinCloud builds a globally leading, "patient-centric" SaaS cloud platform supporting clinical evidence to help domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and devices, and benefit countless patients.




Article illustration

Read the original WeChat article

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.